Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.-Reference-Cited by-同舟云学术

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.

Published:1993-08-21 Issue:6902 Volume:307 Page:469-472
ISSN:0959-8138
Container-title:BMJ
language:en
Short-container-title:BMJ

Author:

Publisher

BMJ

Subject

General Earth and Planetary Sciences,General Environmental Science,General Engineering

Reference15 articles.

1. The impact of treatment with levodopa on Parkinson's disease;Shaw, K.M.; Lees, A.J.; Stern, G.M.;QJMed,1980

2. Considerations in the management of Parkinsonism;Fahn, S.; Calne, D.B.;Neurology,1978

3. Long-term follow-up of early dopa treatment in Parkinson's disease;Markham, C.H.; Diamond, S.G.;Ann Neurol,1986

4. Early dopamine agonist therapy in Parkinson's disease;Rinne, U.K.;Mov Disord,1989

5. A hydrodynamically balanced controlled-release Ldopa/benserazide formulation in the treatment of Parkinson's disease;Lees, A.J.,1988

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta‐Analysis;Movement Disorders Clinical Practice;2024-08-27

2. Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis;European Journal of Pharmacology;2023-09

3. Role of dopamine agonists in Parkinson's disease therapy;Journal of Neural Transmission;2023-05-11

4. Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis;Frontiers in Aging Neuroscience;2023-04-11

5. Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice;International Immunopharmacology;2023-04